# US Anti Ageing Drugs Market

> US Anti-Ageing Drugs Market Research Report: By Drug Class (Serums and Supplements, Antioxidants and Enzymes, Stem Cells, Drugs) and By Application (Skin and Hair, Skeletal and Muscles, Age Related Disorders, Others) - Growth & Industry Forecast 2025 To 2035.

- **Forecast Period:** 2025 - 2035
- **CAGR:** 7.39%
- **2024:** $ 10.5 Billion
- **2025:** $ 11.28 Billion
- **2035:** $ 23 Billion
- **Key Players:** Elysium Health (US), Calico Life Sciences (US), Unity Biotechnology (US), Resverlogix (CA), Sierra Sciences (US), Juvenescence (GB), Life Biosciences (US), Aging Analytics Agency (GB)

**Report ID:** MRFR/Pharma/11755-HCR · **Pages:** 100 · **Author:** Satyendra Maurya & Garvit Vyas · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-anti-ageing-drugs-market-13280

---

## Market Summary

## **US Anti-Ageing Drugs Market Overview**

**As per MRFR analysis, the US Anti-Ageing Drugs Market Size was estimated at 9.43 (USD Billion) in 2023. The US Anti-Ageing Drugs Market Industry is expected to grow from 10.5(USD Billion) in 2024 to 25 (USD Billion) by 2035. The US Anti-Ageing Drugs Market CAGR (growth rate) is expected to be around 8.206% during the forecast period (2025 - 2035).**

### **Key US Anti-Ageing Drugs Market Trends Highlighted**

The US Anti-Ageing Drugs Market is experiencing notable trends shaped by various market drivers. One of the key market drivers is the increasing awareness among the aging population regarding health and appearance. As the baby boomer generation continues to age, there is a greater demand for products that can help reduce the signs of aging, driving growth in this sector. Additionally, advancements in biotechnology and pharmaceuticals are unlocking new anti-aging solutions, promoting the emergence of innovative drugs and therapies. Opportunities are ripe in the market for companies that focus on personalized medicine approaches.

Tailoring anti-aging treatments to individual genetic profiles or lifestyle factors could enhance effectiveness and patient satisfaction.Furthermore, as consumers become more health-conscious, a growing trend is the incorporation of natural and organic ingredients into anti-aging drugs, appealing to those who prioritize holistic approaches to health and wellness. Recent trends indicate a rise in research and development efforts focused on regenerative medicine. US companies are increasingly exploring therapies that not only address exterior aging signs but also tackle underlying cellular and genetic factors.

This shift may lead to novel treatments that extend overall healthspan, rather than just lifespan. The regulatory landscape in the US is also evolving, potentially facilitating faster approval processes for innovative [anti-aging drugs](../../../reports/anti-ageing-drugs-market-3504). As these trends continue to develop, the market is positioning itself for transformative growth, driven by the desires of consumers to maintain their vitality and appearance as they age.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **US Anti-Ageing Drugs Market Drivers**

### **Increasing Aging Population**

The US Anti-Ageing Drugs Market Industry is significantly driven by the continuously increasing aging population in the United States. According to the U.S. Census Bureau, the population aged 65 and older is expected to double from approximately 52 million in 2018 to over 95 million by 2060. This demographic shift is leading to a higher demand for anti-aging treatments, as older adults seek medical and pharmaceutical interventions to maintain their vitality and health.

Moreover, the American Association of Retired Persons (AARP) indicates that older individuals are more inclined to invest in healthcare and wellness, which includes anti-aging drugs. As a result, pharmaceutical companies are focusing on developing innovative anti-aging solutions to cater to this growing market segment, projecting a notable increase in the revenue generated from anti-aging drugs as the market responds to this demographic trend.

### **Technological Advancements in Drug Development**

Advancements in technology play a crucial role in shaping the US Anti-Ageing Drugs Market Industry. Recent breakthroughs in Research and Development (R&D) have led to the formulation of more effective anti-aging drugs that target various aging-related issues such as wrinkles, cognitive decline, and metabolic syndromes. The National Institutes of Health (NIH) has allocated considerable funding for the investigation into aging processes, with a reported funding of over $4 billion annually.

This funding supports innovative therapeutic approaches, including gene therapy and regenerative medicine, thereby enhancing the effectiveness of anti-aging treatments. As technology continues to evolve, the enhancement in drug efficacy is expected to boost consumer confidence and expand the market, catering to the rising demand for age-related medical therapies.

### **Growing Health and Wellness Awareness**

The increasing awareness of health and wellness among the American population is driving the US Anti-Ageing Drugs Market Industry. As people are becoming more health-conscious, there is a notable shift towards preventive healthcare measures, including the utilization of anti-aging drugs. According to the National Center for Complementary and Integrative Health (NCCIH), the interest in dietary supplements and preventative therapies has seen a marked increase, with an estimated 20% of Americans regularly using vitamins and supplements for anti-aging purposes.

This heightened focus on maintaining health and appearance is pushing pharmaceutical companies to invest in marketing and developing anti-aging products to meet consumer demands, ultimately contributing to market growth.

### **Rise in Affluent Consumers**

The rise in affluent consumers in the United States is a significant driver of the US Anti-Ageing Drugs Market Industry. With increasing disposable incomes, more people are willing to invest in health and beauty products, including anti-aging drugs. The U.S. Bureau of Labor Statistics indicates that the upper-middle-class sector has been growing steadily, with households earning above $100,000 exhibiting a strong interest in maintaining their youthfulness through pharmaceutical interventions.

This demographic not only has the financial means to purchase anti-aging products but also tends to prioritize health and wellness. Pharmaceutical firms are strategically positioning their products to cater to this affluent market segment, thereby propelling the growth of the anti-aging drugs industry in the United States.

## **US Anti-Ageing Drugs Market Segment Insights**

### **Anti-Ageing Drugs Market Drug Class Insights**

The US Anti-Ageing Drugs Market within the Drug Class segment presents a diverse and rapidly evolving landscape, reflecting a significant focus on skincare and longevity enhancement. The market is marked by the proliferation of various product categories that cater to varying consumer needs, including Serums and Supplements, Antioxidants and Enzymes, Stem Cells, and Drugs. Among these, Serums and Supplements serve as essential tools for hydration and nourishment, frequently combining active ingredients to enhance skin elasticity and texture. Consumers are increasingly leaning towards formulations that promise visible results, leading to a robust demand for innovative products.

This trend is supported by the aging population in the United States, which emphasizes the need for effective anti-ageing solutions in the marketplace.Antioxidants and Enzymes have gained traction due to their roles in combating oxidative stress and promoting skin health. These compounds help neutralize free radicals, making them crucial in delaying the ageing process and contributing to overall wellness. The growing awareness of the harmful effects of environmental factors, such as UV rays and pollution, underscores the importance of incorporating these active ingredients into daily routines.

The emphasis on natural and organic products also drives growth within this sector, as consumers seek safer and more sustainable options for skin and health care.Meanwhile, Stem Cells represent a cutting-edge approach within the anti-ageing treatments arena. Their regenerative capabilities make them appealing to a market segment motivated by advancements in science and technology. Stem Cell therapies are often viewed as the future of anti-ageing solutions, promising unparalleled results that could revolutionize how aging is approached. The rising investment in Research and Development further fuels innovation, with ongoing studies exploring the potential of stem cells in tissue repair and rejuvenation.

Drugs specifically targeting ageing-related conditions form another vital aspect of the Drug Class segment. As the US population ages, there is an increasing demand for pharmaceuticals that can address age-related diseases effectively, leading to an expanding market focusing on longevity and enhanced physical capabilities. Factors such as lifestyle changes, growing interest in preventive healthcare, and government initiatives aiming to improve the health span of citizens contribute to the overall growth in this area.The US Anti-Ageing Drugs Market segmentation highlights a significant intersection of science, consumer preferences, and market dynamics, with each category contributing to a comprehensive approach to anti-ageing solutions.

The ongoing innovation and integration of various therapeutic agents not only meet the demands of a diverse consumer base but also reflect broader industry trends toward personalization and enhanced user experience. The robust competitive landscape, driven by major companies and emerging start-ups alike, positions the Drug Class segment as a core foundation for future opportunities within the overarching anti-ageing market.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Anti-Ageing Drugs Market Application Insights**

The Application segment of the US Anti-Ageing Drugs Market is a crucial area showcasing diverse opportunities and growth potential. This segment encompasses various categories such as Skin and Hair, Skeletal and Muscles, Age Related Disorders, and Others, reflecting the multifaceted nature of anti-ageing solutions. Within this landscape, the Skin and Hair category is particularly significant as it addresses the cosmetic needs and aesthetic concerns of the ageing population, who prioritize maintaining youthful skin and healthy hair.

The Skeletal and Muscles segment captures attention due to the increasing prevalence of age-related musculoskeletal issues, which require effective treatments to enhance mobility and quality of life.Moreover, Age Related Disorders represent a vital aspect, with therapies focused on conditions like Alzheimer’s and cardiovascular diseases becoming more prevalent as the population ages. Additionally, the 'Others' category includes emerging therapies and experimental treatments that are gaining traction, presenting new avenues for innovation. The trends driving the market include rising consumer awareness, advancements in research and development, and a growing geriatric population that demands effective anti-ageing solutions.

The US Anti-Ageing Drugs Market segmentation presents a comprehensive framework to understand the dynamics of consumer needs and preferences in pursuing longevity and wellness.

## **US Anti-Ageing Drugs Market Key Players and Competitive Insights**

The US Anti-Ageing Drugs Market is characterized by rapid advancements in pharmaceutical research aimed at mitigating the effects of aging through various innovative treatments. This sector encompasses a range of products designed to promote longevity, enhance vitality, and address age-related health conditions. Competitive insights indicate that key players are continuously investing in research and development, strengthening their product pipelines, and forming strategic collaborations to maintain a foothold in this growing market. The increasing prevalence of age-related diseases, combined with a burgeoning aging population in the US, has further intensified competition among existing companies seeking to capture significant market share.

Moreover, the demand for anti-aging therapies, particularly those supported by scientific reviews and clinical trials, adds another layer of complexity to this competitive landscape.Merck and Co has carved out a notable presence within the US Anti-Ageing Drugs Market, leveraging its extensive expertise in pharmaceutical development and a robust portfolio of medications that target various indicators of aging. The company's significant investment in cutting-edge research positions it strongly against competitors, enabling the development of effective therapies that cater to the evolving needs of an aging population.

Moreover, Merck and Co's established reputation in the healthcare community fosters trust and brand loyalty among consumers and healthcare providers alike. This, along with their unwavering commitment to quality and innovation, solidifies their competitive edge in an industry where new entrants are frequently emerging.AstraZeneca also showcases a stronghold in the US Anti-Ageing Drugs Market through its portfolio of key products aimed at alleviating age-related health concerns. The company emphasizes a strategic approach, focusing on research and development to expand its offerings in this sector. AstraZeneca's strengths lie in its innovative drug development capabilities, allowing the introduction of highly effective treatments.

Furthermore, the company has actively pursued mergers and acquisitions to bolster its presence in the market, propelling advancements in anti-aging solutions. By aligning with additional firms and leveraging synergies, AstraZeneca continues to enhance its market presence. This strategic orientation, coupled with a commitment to addressing customers' needs, solidifies their position as a competitive player in the US Anti-Ageing Drugs Market.

### **Key Companies in the US Anti-Ageing Drugs Market Include**

## **US Anti-Ageing Drugs Market Industry Developments**

The US Anti-Ageing Drugs Market has seen significant advancements and collaborations recently. Companies like Merck and Co, AstraZeneca, and Novartis continue to focus on innovative solutions for age-related health issues. In June 2023, Bristol-Myers Squibb announced its acquisition of a promising biotechnology firm to enhance its Research and Development capabilities in the anti-ageing sector. Meanwhile, Eli Lilly unveiled a novel therapeutic agent aimed at mitigating age-related cognitive decline, highlighting the trend towards preventive treatments.

Growth in market valuation has been driven by increased demand for anti-ageing products, with a valuation projected to exceed USD 300 billion by 2024. Companies such as Regeneron Pharmaceuticals and Abbott have entered niche segments, focusing on targeted therapies that promote longevity. Additionally, market dynamics have shifted due to consumer awareness regarding health and wellness, prompting firms like GlaxoSmithKline and Pfizer to invest heavily in marketing anti-ageing solutions. Over the past two years, emerging research has emphasized the importance of genetic factors in ageing, further stimulating interest and funding in this evolving market landscape.

## **US Anti-Ageing Drugs Market Segmentation Insights**

### **Anti-Ageing Drugs Market Drug Class Outlook**

### **Anti-Ageing Drugs Market Application Outlook**

- Skin and Hair
- Skeletal and Muscles
- Age Related Disorders
- Others

## Market Drivers

### Growing Aging Population

The increasing aging population in the US is a primary driver for the anti ageing-drugs market. As life expectancy rises, the demand for effective anti-aging solutions intensifies. By 2030, it is projected that 20% of the US population will be aged 65 and older, leading to a heightened focus on health and wellness among older adults. This demographic shift creates a substantial market opportunity for anti ageing-drugs, as older individuals seek to maintain their vitality and quality of life. The anti ageing-drugs market is likely to benefit from this trend, as pharmaceutical companies develop targeted therapies to address age-related conditions. Furthermore, the financial implications are significant, with the market expected to reach $300 billion by 2025, indicating a robust growth trajectory fueled by the aging population.

### Rising Consumer Awareness

Consumer awareness regarding health and wellness is on the rise, significantly impacting the anti ageing-drugs market. Individuals are increasingly informed about the benefits of anti-aging treatments, leading to a surge in demand for products that promise to enhance longevity and vitality. This trend is supported by the proliferation of information through digital platforms, where consumers actively seek knowledge about anti-aging solutions. The anti ageing-drugs market is witnessing a shift as consumers prioritize preventive healthcare, driving sales of supplements and pharmaceuticals aimed at combating the effects of aging. Market data suggests that the sector could experience a growth rate of 8% annually, as more individuals invest in their health and seek out innovative anti-aging therapies.

### Advancements in Biotechnology

Technological advancements in biotechnology are revolutionizing the anti ageing-drugs market. Innovations in genetic research and regenerative medicine are paving the way for new treatments that target the biological mechanisms of aging. Companies are increasingly investing in biopharmaceuticals that utilize stem cell therapy and gene editing to develop effective anti-aging solutions. The anti ageing-drugs market is likely to see a surge in products that leverage these advancements, potentially leading to breakthroughs in age-related disease management. As of 2025, the market for biotechnology in anti-aging is projected to reach $150 billion, reflecting the growing interest and investment in this area. This trend indicates a promising future for consumers seeking cutting-edge therapies to enhance their longevity.

### Regulatory Support for Innovation

Regulatory bodies in the US are increasingly supportive of innovation within the anti ageing-drugs market. Streamlined approval processes for new drugs and therapies are encouraging pharmaceutical companies to invest in research and development. This regulatory environment fosters a climate of innovation, allowing for the rapid introduction of novel anti-aging treatments. The anti ageing-drugs market is likely to benefit from this supportive framework, as it enables companies to bring their products to market more efficiently. Recent data indicates that the average time for drug approval has decreased by 20%, which could lead to a surge in new anti-aging therapies. This regulatory support is essential for sustaining growth in the market and meeting the evolving needs of consumers.

### Increased Focus on Preventive Healthcare

The shift towards preventive healthcare is significantly influencing the anti ageing-drugs market. As healthcare costs continue to rise, there is a growing emphasis on maintaining health rather than merely treating diseases. This proactive approach encourages individuals to seek anti-aging solutions that can help mitigate age-related health issues before they arise. The anti ageing-drugs market is adapting to this trend by offering products that promote wellness and longevity. Market analysis indicates that the preventive healthcare sector is expected to grow by 10% annually, with anti-aging drugs playing a crucial role in this transformation. This focus on prevention not only benefits consumers but also aligns with healthcare providers' goals of reducing long-term medical expenses.

## Future Outlook

The [Anti Ageing Drugs Market](https://www.marketresearchfuture.com/reports/anti-ageing-drugs-market-3504) is projected to grow at a 7.39% CAGR from 2025 to 2035, driven by technological advancements, increasing consumer awareness, and rising demand for longevity solutions.

**New opportunities:**

- Development of personalized anti ageing therapies leveraging genetic profiling. Expansion of telehealth services for remote consultations and prescriptions. Investment in AI-driven research for novel anti ageing compounds.

By 2035, the market is expected to achieve substantial growth, driven by innovation and consumer demand.

## Segment Insights

### By Drug Class: Serums and Supplements (Largest) vs. Antioxidants and Enzymes (Fastest-Growing)

In the US anti ageing-drugs market, Serums and Supplements hold the largest market share, driven by consumer preferences for topical applications and nutritional supplements that promise rejuvenation. Meanwhile, Antioxidants and Enzymes are emerging as a significant category, contributing to overall growth with their innovative formulations that target free radicals and promote skin vitality. 

Growth trends reveal a strong inclination towards preventive care and holistic wellness, leading to an uptick in demand for both these categories. Additionally, advancements in formulations and clinical research supporting efficacy are bolstering consumer confidence. The trend towards natural and organic ingredients is also influencing purchasing behavior, enhancing the position of Antioxidants and Enzymes as they resonate with health-conscious consumers.

Serums and Supplements (Dominant) vs. Antioxidants and Enzymes (Emerging)

Serums and Supplements are characterized by their effectiveness in delivering active ingredients directly to the skin, making them highly sought after in the US anti ageing-drugs market. With a focus on enhancing skin appearance, these products often integrate various active components like peptides and vitamins that cater to consumer preferences for quick and visible results. In contrast, Antioxidants and Enzymes, while still gaining traction in the market, are valued for their ability to protect and rejuvenate skin through their unique mechanisms. As the fastest-growing segment, they appeal to those seeking innovative solutions backed by scientific research, thus compelling brands to explore new formulations that leverage natural sources, aligning with the growing trend of green beauty.

### By Application: Skin and Hair (Largest) vs. Age Related Disorders (Fastest-Growing)

In the US anti ageing-drugs market, the distribution of market share among various application segments reveals that the Skin and Hair category holds the largest share, driven primarily by the increasing focus on beauty and wellness. This segment benefits from a growing demand for anti-ageing products, as consumers become more aware of skin health. Conversely, Age Related Disorders are quickly gaining traction, attributed to the ageing population and rising incidences of age-related health issues, which necessitate effective treatment options.

The growth trends in the US anti ageing-drugs market are significantly influenced by advancements in pharmaceutical research and the development of innovative products. The Skin and Hair segment continues to thrive due to a blend of natural and synthetic formulations aimed at reversing signs of aging. Meanwhile, Age Related Disorders are being propelled by an escalating public awareness of health and longevity, leading to increased investment in targeted therapies and supportive treatments designed for older adults.

Skin and Hair (Dominant) vs. Age Related Disorders (Emerging)

Skin and Hair is the dominant application segment within the US anti ageing-drugs market, characterized by its extensive array of products that address aesthetic concerns such as wrinkles, fine lines, and skin elasticity. This segment has a broad consumer base, from young adults seeking preventive care to older individuals desiring restorative outcomes. Various formulations, including creams, serums, and injectable treatments, cater to diverse preferences. In contrast, Age Related Disorders is an emerging segment that focuses on medical concerns linked to age, such as cognitive decline and osteoporosis. With an increasing emphasis on quality of life for older adults, this segment is rapidly evolving, driven by ongoing research and a growing societal push for effective ageing solutions.

## Competitive Benchmarking

The anti ageing-drugs market is currently characterized by a dynamic competitive landscape, driven by a confluence of innovation, strategic partnerships, and a growing consumer demand for longevity solutions. Key players such as Elysium Health (US), Calico Life Sciences (US), and Unity Biotechnology (US) are at the forefront, each adopting distinct strategies to carve out their market positions. Elysium Health (US) focuses on developing scientifically-backed supplements aimed at cellular health, while Calico Life Sciences (US) emphasizes research and development in genetic and molecular biology to combat age-related diseases. Unity Biotechnology (US) is pioneering therapies that target cellular senescence, indicating a strong operational focus on innovative drug development. Collectively, these strategies not only enhance their competitive edge but also contribute to a rapidly evolving market landscape.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The competitive structure of the anti ageing-drugs market appears moderately fragmented, with several players vying for market share. However, the influence of major companies is substantial, as they leverage their resources and expertise to shape industry standards and consumer expectations.
In October Elysium Health (US) announced a partnership with a leading research institution to advance its clinical trials for a new anti ageing supplement. This collaboration is strategically significant as it not only bolsters Elysium's research capabilities but also enhances its credibility in the market, potentially leading to increased consumer trust and sales. The partnership underscores the importance of scientific validation in the anti ageing sector, where consumers are increasingly discerning about product efficacy.
In September Calico Life Sciences (US) revealed a breakthrough in its research on telomere extension, which could significantly impact cellular aging. This development is crucial as it positions Calico at the cutting edge of anti ageing research, potentially leading to novel therapies that could redefine treatment paradigms. The implications of such advancements could be profound, influencing both market dynamics and consumer perceptions of longevity solutions.
In August Unity Biotechnology (US) secured $50M in funding to accelerate its clinical trials for a new senolytic drug. This financial boost is indicative of investor confidence in Unity's innovative approach to combating age-related diseases. The funding will likely enhance Unity's operational capabilities, allowing for faster development timelines and a stronger competitive position in the market.
As of November current trends in the anti ageing-drugs market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence in research and development processes. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in navigating complex regulatory environments and advancing scientific research. Looking ahead, competitive differentiation is expected to evolve, with a marked shift from price-based competition towards innovation, technological advancements, and supply chain reliability. This transition suggests that companies that prioritize research and development, alongside sustainable practices, will likely emerge as leaders in the anti ageing-drugs market.

## Recent News & Developments

The US Anti-Ageing Drugs Market has seen significant advancements and collaborations recently. Companies like Merck and Co, AstraZeneca, and Novartis continue to focus on innovative solutions for age-related health issues. In June 2023, Bristol-Myers Squibb announced its acquisition of a promising biotechnology firm to enhance its Research and Development capabilities in the anti-ageing sector. Meanwhile, Eli Lilly unveiled a novel therapeutic agent aimed at mitigating age-related cognitive decline, highlighting the trend towards preventive treatments.

Growth in market valuation has been driven by increased demand for anti-ageing products, with a valuation projected to exceed USD 300 billion by 2024. Companies such as Regeneron Pharmaceuticals and Abbott have entered niche segments, focusing on targeted therapies that promote longevity. Additionally, market dynamics have shifted due to consumer awareness regarding health and wellness, prompting firms like GlaxoSmithKline and Pfizer to invest heavily in marketing anti-ageing solutions. Over the past two years, emerging research has emphasized the importance of genetic factors in ageing, further stimulating interest and funding in this evolving market landscape.

## Report Scope

| MARKET SIZE 2024 | 10.5(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 11.28(USD Billion) |
| MARKET SIZE 2035 | 23.0(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.39% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Elysium Health (US), Calico Life Sciences (US), Unity Biotechnology (US), Resverlogix (CA), Sierra Sciences (US), Juvenescence (GB), Life Biosciences (US), Aging Analytics Agency (GB) |
| Segments Covered | Drug Class, Application |
| Key Market Opportunities | Emerging biotechnologies and personalized medicine are reshaping the anti ageing-drugs market landscape. |
| Key Market Dynamics | Rising consumer demand for innovative anti ageing-drugs drives competitive dynamics and regulatory scrutiny in the market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What was the overall valuation of the US anti ageing-drugs market in 2024?**
A: The overall market valuation was $10.5 Billion in 2024.

**Q: What is the projected market valuation for the US anti ageing-drugs market by 2035?**
A: The projected valuation for 2035 is $23.0 Billion.

**Q: What is the expected CAGR for the US anti ageing-drugs market during the forecast period 2025 - 2035?**
A: The expected CAGR during the forecast period 2025 - 2035 is 7.39%.

**Q: Which segment had the highest valuation in the US anti ageing-drugs market in 2024?**
A: In 2024, the Drugs segment had the highest valuation at $4.2 Billion.

**Q: What is the projected valuation for the Serums and Supplements segment by 2035?**
A: The projected valuation for the Serums and Supplements segment by 2035 is $7.0 Billion.

**Q: Which key player in the US anti ageing-drugs market focuses on biotechnology?**
A: Unity Biotechnology is a key player that focuses on biotechnology in the US anti ageing-drugs market.

**Q: What was the valuation of the Age Related Disorders segment in 2024?**
A: The valuation of the Age Related Disorders segment in 2024 was $4.0 Billion.

**Q: What is the projected growth for the Antioxidants and Enzymes segment by 2035?**
A: The projected growth for the Antioxidants and Enzymes segment by 2035 is to $4.5 Billion.

**Q: Which company is known for its research in stem cell therapies within the US anti ageing-drugs market?**
A: Sierra Sciences is known for its research in stem cell therapies within the US anti ageing-drugs market.

**Q: What is the expected valuation for the Others segment by 2035?**
A: The expected valuation for the Others segment by 2035 is $2.8 Billion.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-anti-ageing-drugs-market-13280*